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was 38 years. Age and importance of religion were signiﬁcant
predictors of non-trader status. People of younger age, age group
18 to 25 years (OR = 0.97, p = 0.0345) and those who placed
a higher importance on religion in their lives (OR = 5.08, p =
0.0131) were more likely to be non-traders. Gender and race/
ethnicity had no association. CONCLUSIONS: Younger age and
greater importance of religion in a person’s life were signiﬁcantly
associated with being predictors of non-trader status.
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DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED
USEFULNESS SCALE TO EVALUATE ANTIEPILEPTIC
PHARMACOTHERAPY IN PATIENTS WITH EPILEPSY
Brown LM, Mulani P, Cifaldi M,Ashraf T
Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVE: Patients’ perceptions of the value of their
antiepileptic medications are important factors in assessing
antiepileptic drug therapy. We developed and validated a scale
to combine patient-reported efﬁcacy, convenience and tolerabil-
ity of antiepileptic pharmacotherapy into a single measure of
overall usefulness. METHODS: Neurologists in two practices
assigned patients a priori to either a “doing well” or “not doing
well” group based upon clinical assessment of efﬁcacy, tolera-
bility and convenience of each patient’s antiepileptic medication.
Adult outpatients on antiepileptic medications completed a four-
item self-administered questionnaire. Patients scored the over-
all usefulness, efﬁcacy, tolerability and convenience of their
antiepileptic pharmacotherapy on visual analogue scales ranging
from 0 to 100. Fisher’s exact test was used to determine sys-
tematic differences in demographic characteristics or neurolo-
gist’s assessment of the two groups. Differences between groups
in mean overall usefulness and component scores were assessed
using the t-test. A multivariate model was used to assess weights
of efﬁcacy, tolerability and convenience on the overall usefulness
score. RESULTS: Sixty patients completed the questionnaire.
Sixty percent (60%) were classiﬁed as “doing well” and 24
(40%) as “not doing well” a priori on antiepileptic medication.
Both groups had similar demographic characteristics. The “not
doing well” group had signiﬁcantly more problems with efﬁcacy,
tolerability and convenience than the “doing well” group (p <
0.001). The mean overall usefulness score was higher for the
“doing well” group (88) compared to the “not doing well” group
(53) even after controlling for all demographic variables (p <
0.0001). Similar results were observed for efﬁcacy and tolera-
bility scores. No individual domain (efﬁcacy, tolerability, conve-
nience) had a disproportionate inﬂuence on the overall usefulness
score. CONCLUSIONS: This patient-reported usefulness scale
for antiepileptic drug therapy has potential application in
research and clinical settings to discriminate between patients
whose antiepileptic pharmacotherapy is efﬁcacious, tolerable
and convenient and those whose antiepileptic pharmacotherapy
is not.
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OBJECTIVE: The impact on health economic outcomes of using
either Framingham or United Kingdom Prospective Diabetes
Study (UKPDS) risk equations for stroke and myocardial infarc-
tion (MI) was evaluated. The effects of interventions aimed at
lipid proﬁle improvement, blood pressure control, or improved
glycemic control were modeled in typical type 2 diabetes cohorts
using either the Framingham or the UKPDS risk formulae
embedded in a documented, validated type-2 diabetes simulation
model. METHODS: The progression of diabetes complications
including both micro- and macrovascular disease was simulated.
Total lifetime costs/patient (TC), life expectancy (LE), and
costs/life-year gained (C/LYG) of 3 hypothetical interventions
affecting either lipid proﬁle (LDL lowered from 150–120mg/dl
and HDL raised from 35 to 45mg/dl costing $300/year/patient),
blood pressure (systolic blood pressure reduced from 170 to 140
mmHg costing $300/year), or glycemic control (HbA1c lowered
from 10 to 8.5%, costing $300/year) were calculated. RESULTS:
Using Framingham formulae consistently underestimated
improvements in LE when compared to using UKPDS formulae.
Due to the interplay of a number of factors, effects on TC and
C/LYG were less consistent. In the lipid-intervention, LE
improved by 0.41 years using Framingham formulae, and by
0.74 years using UKPDS. TC were increased by ~ $3400/patient
using both sets of formulae, but C/LYG were $13,094 using
Framingham and $7103 using UKPDS. In the blood pressure
intervention, LE improved 0.40 or 0.52 years using Framingham
formulae or UKPDS respectively. TC were decreased by around
$5814/patient using Framingham, and by $6591 using UKPDS.
In the glycemic control intervention, LE improve 0.37 years
using Framingham formulae, and by 0.66 years using UKPDS.
TC were decreased by $20,072/patient and by $4948 using
Framingham or UKPDS respectively, but C/LYG were $13,094
using Framingham and $7103 using UKPDS. CONCLUSIONS:
The choice of cardiovascular disease risk formulae has an impor-
tant impact on long term health economic outcomes of type-2
diabetes patients, and the predicted cost effectiveness of 
interventions.
(For abstract DB2 see page 342) HM1
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OBJECTIVES: In the past contradictory results on the effective-
ness of various disease management programs (DMP) for 
Diabetes mellitus (D.m.) have been reported. Beyond the chosen
care process, it seems particularly important to select only those
patients with the highest probability to beneﬁt from such a
program by risk stratiﬁcation to optimize the effectiveness
(patient outcome) and efﬁciency of DMPs. Here, a new method
is presented to stratify cohorts and identify patients using indi-
vidualized predictions with the D.m. disease model Mellibase.
METHODS: A Markov based disease model was used to calcu-
late individual expected medical and economic outcomes (ﬁve
typical complications of D.m) for 121 real-life cases on the basis
of baseline clinical parameters like HbA1c, blood pressure and
lipid levels. Two kinds of parameters were then used to select
one third of all cases: 1) Clinical parameters (those cases with
the worst values), and 2) computed parameters like life-
expectancy (those cases with the highest theoretical potential for
improvement). All stratiﬁcation parameters were then tested for
actual improvement of outcomes with real pre-post data taken
from a German DMP with type-2-diabetics. RESULTS: A strat-
